<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>The Neuroscience Journal of Shefaye Khatam</title>
<title_fa>مجله علوم اعصاب شفای خاتم</title_fa>
<short_title>Shefaye Khatam</short_title>
<subject>Medical Sciences</subject>
<web_url>http://shefayekhatam.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2322-1887</journal_id_issn>
<journal_id_issn_online>2345-4814</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/shefa</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>fa</language>
<pubdate>
	<type>jalali</type>
	<year>1396</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2017</year>
	<month>4</month>
	<day>1</day>
</pubdate>
<volume>5</volume>
<number>2</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>ar</language>
	<article_id_doi></article_id_doi>
	<title_fa>P 87: The Amyloid Beta as a Therapeutic Target in Alzheimer Disease</title_fa>
	<title>P 87: The Amyloid Beta as a Therapeutic Target in Alzheimer Disease</title>
	<subject_fa>تحقیقات پایه در علوم اعصاب</subject_fa>
	<subject>Basic research in Neuroscience</subject>
	<content_type_fa>مروری</content_type_fa>
	<content_type>Review --- Open Access, CC-BY-NC</content_type>
	<abstract_fa>&lt;table border=&quot;0&quot; cellpadding=&quot;5px&quot; cellspacing=&quot;2&quot; dir=&quot;rtl&quot; id=&quot;table_article&quot; style=&quot;font-family: Tahoma; background-color: rgb(251, 250, 249); break-inside: avoid !important;&quot; width=&quot;100%&quot;&gt;
	&lt;tbody style=&quot;break-inside: avoid !important; font-size: 12px; margin-top: 0px; line-height: 2.2; margin-bottom: 0px; text-align: justify;&quot;&gt;
		&lt;tr style=&quot;break-inside: avoid !important;&quot;&gt;
			&lt;td class=&quot;abstractmed&quot; colspan=&quot;2&quot; style=&quot;break-inside: avoid !important;&quot;&gt;
			&lt;p style=&quot;font-size: 12px; margin-top: 0px; margin-bottom: 0px; text-align: center;&quot;&gt;&lt;span style=&quot;color: rgb(0, 0, 0); font-size: 12px;&quot;&gt;لطفاً به چکیده انگلیسی مراجعه شود.&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style=&quot;break-inside: avoid !important;&quot;&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;&lt;/p&gt;
</abstract_fa>
	<abstract>&lt;p&gt;Alzheimer disease (AD) is a neurodegenerative disorder marked by cognitive and behavioral impairment. Amyloid beta (A&amp;beta;) peptides are involved in AD as the main component of amyloid plaques found in the brain. Recent in vivo and in vitro studies have shown that there is a lot of substances that alter A&amp;beta; pathogenesis of AD. A&amp;beta; induces toxicity lead to increasing ROS. In the other hand, 5-HT6 and Aloe arborescence recently reported to protect cells from this effect. Additionally, A&amp;beta; oligomers interact with neurons through Nrx2a and NL1 receptors by blocking these receptors; one can reduce the A&amp;beta;-induced memory impairment. Moreover, A&amp;beta; aggregation correlates with high concentration of Fe (III) and Cu (II). And chelators decreased significantly aggregation of A&amp;beta; in synaptic cleft. By knowing the mechanism of A&amp;beta; toxicity, new therapeutic approaches can be developed to prevent AD or alleviate disability caused by it. JC-124 treatment leads to decrease levels of A&amp;beta; deposition. Bosentan, a dual endothelin receptor antagonist, offers protection against A&amp;beta;-induced endothelial damage. Anti Nrx2a andante NL1 reduces A&amp;beta;-induced memory impairment in mice. Clicaquinol inhibits disaggregation of A&amp;beta; at low pHs. In this article we review the substances that have a role in the toxicity of A&amp;beta; and can be considered as a new target for the management of AD.&lt;/p&gt;
</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Amyloid beta, Alzheimer disease, Neurodegenerative, Treatment</keyword>
	<start_page>118</start_page>
	<end_page>118</end_page>
	<web_url>http://shefayekhatam.ir/browse.php?a_code=A-10-24-937&amp;slc_lang=ar&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Mohammad Javad </first_name>
	<middle_name></middle_name>
	<last_name>Imen</last_name>
	<suffix></suffix>
	<first_name_fa>Mohammad Javad </first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>Imen</last_name_fa>
	<suffix_fa></suffix_fa>
	<email>imenmj912@gmail.com</email>
	<code>100319475328460012061</code>
	<orcid>100319475328460012061</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Islamic Azad University, Mashhad Branch, Medicine Faculty, Mashhad, Iran </affiliation>
	<affiliation_fa>Islamic Azad University, Mashhad Branch, Medicine Faculty, Mashhad, Iran </affiliation_fa>
	 </author>


	<author>
	<first_name>Reza </first_name>
	<middle_name></middle_name>
	<last_name>Bayattork</last_name>
	<suffix></suffix>
	<first_name_fa>Reza </first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>Bayattork</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460012062</code>
	<orcid>100319475328460012062</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Islamic Azad University, Mashhad Branch, Medicine Faculty, Mashhad, Iran </affiliation>
	<affiliation_fa>Islamic Azad University, Mashhad Branch, Medicine Faculty, Mashhad, Iran </affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
